Safety of Topical Minoxidil Solution: A One-Year,Prospective,Observational Study

Abstract

French

Background:

Topical minoxidil solution (TMS) is widely used for androgenetic alopecia (AGA), and this is the first report of a large safety trial.

Objectives:

The aim of the study was to evaluate the safety profile of TMS by comparing hospitalization and death rates among subjects using TMS with controls. Cardiovascular safety and pregnancy outcomes were evaluated, and usage patterns were described.

Methods:

All subjects were followed at baseline, 3, 6, 9, and 12 months. Usage patterns, pregnancy status, overnight hospital stays, and cardiovascular risk factors were evaluated. Subjects rated effectiveness of TMS in the treatment of AGA. Statistical analyses were conducted to determine if TMS was associated with an increased risk of death or hospitalization.

Results:

TMS is a safe and effective treatment for AGA. There were no increases in cardiovascular events and no apparent increased risk for adverse pregnancy outcomes.

Conclusions:

This large, prospective study demonstrated the overall safety of TMS in the treatment of AGA.

Get full access to this article

View all access options for this article.

References

Meidan

Touitou

Treatments for androgenetic alopecia and alopecia areata: Current options and future prospects. Drugs 2001; 61:53–69.

Nielsen

Reichel

Alopecia: Diagnosis and management. Am Fam Physician 1995; 51:1513–1522.

Olsen

Androgenetic alopecia. In: Olsen

, ed. Disorders of hair growth. New York: McGraw-Hill, 1994, pp 257–283.

Kligman

Freeman

History of baldness: From magic to medicine. Clin Dermatol 1988; 6:83–88.

Cash

. The psychosocial consequences of androgenetic alopecia: A review of the research literature. Br J Dermatol 1999; 141:398–405.

Davies

Hair apparent. Nature 1998; 391:537–539.

DeVillez

Jacobs

Szpunar

, Androgenetic alopecia in the female: Treatment with 2% topical minoxidil solution. Arch Dermatol 1994; 130:303–307.

Price

Menefee

Strauss

. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41:717–721.

Chidsey

3rd Gottlieb

. The pharmacologic basis of antihypertensive therapy: The role of vasodilator drugs. Prog Cardiovasc Dis 1974; 27:99–113.

10.

Baumgartner

Spindler

. The effects of topical minoxidil in untreated hypertensives (protocol M7410/0084). Study report 7410/85/9157, November 20, 1985.

11.

Spindler

. The safety of topical minoxidil solution in the treatment of pattern baldness: The results of a 27-center trial. Clin Dermatol 1988; 6:200–211.

12.

Spindler

Corak

Rohrstaff

, Topical minoxidil: Long-term safety information from studies in males and females with androgenetic alopecia. Upjohn Study Report 9157-93-002. Peapack, NJ: Pharmacia and Upjohn Consumer Healthcare, March 22, 1993.

13.

Herrera

D'Agostino

Gerstman

, Baldness and coronary heart disease rates in men from the Framingham Study. Am J Epidemiol 1995; 142:828–833.

14.

Lotufo

Chae

Ajani

, Male pattern baldness and coronary heart disease: The Physicians' Health Study. Arch Intern Med 2000; 160:165–171.

15.

Matilainen

Makinen

Keinanen–Kiukaanniemi

. Early onset of androgenetic alopecia associated with early severe coronary heart disease: A population-based, case-control study. J Cardiovasc Risk 2001; 8:147–151.

16.

Persson

Johansson

. The Kockum study. Twenty-two-year follow-up: Coronary heart disease in a population in the south of Sweden. Acta Med Scand 1984; 216:485–493.

17.

Sasmaz

Senol

Ozcan

, The risk of coronary heart disease in men with androgenetic alopecia. J Eur Acad Dermatol Venereol 1999; 12:123–125.

18.

Trevisan

Farinaro

Krogh

, Baldness and coronary heart disease risk factors. J Clin Epidemiol 1993; 46:1213–1218.